Loading...
Market
How many patients will be treated with Miplyffa by Dec 31, 2024?
2
Resolution / Starting Odds
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Reports from Zevra Therapeutics and medical registries
Story
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C
Sep 20, 2024, 03:42 PM
The U.S. Food and Drug Administration (FDA) has approved the first oral medication to treat Niemann-Pick disease, type C (NPC). The drug, developed by Zevra Therapeutics and named Miplyffa (arimoclomol), is approved in combination with miglustat for patients aged 2 and older. This marks the first treatment to receive approval for this rare and fatal genetic disorder. The approval was announced on Friday. Zevra Therapeutics is listed under the ticker symbol ZVRA.
View original story
Similar markets
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Less than 50,000 • 25%
50,000 to 75,000 • 25%
75,000 to 100,000 • 25%
More than 100,000 • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,000 to 15,000 • 25%
More than 15,000 • 25%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
0-10,000 • 25%
10,001-20,000 • 25%
20,001-30,000 • 25%
Over 30,000 • 25%